Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Spinal Fluid Biomarkers Detect Early Alzheimer's Disease

By LabMedica International staff writers
Posted on 07 Mar 2012
Abnormal levels of seven proteins in cerebrospinal fluid could be markers for the early stages of Alzheimer's disease (AD), which would improve diagnosis. More...


Biomarker ions were determined using mass spectroscopy to identify the seven proteins that are diagnostic of prodromal AD which were then followed by bioinformatic analysis that generated a set of potential biomarkers.

Scientists at Nottingham Trent University (Nottingham, UK) analyzed samples of lumbar cerebrospinal fluid (CSF) from 33 clinically diagnosed AD cases, 20 age-matched controls, and 10 mild cognitive impairment (MCI) patients to obtain proteomic profiles.

The panel of seven peptide biomarker ions was able to discriminate AD patients from controls with a median accuracy of 95% (sensitivity 85%, specificity 97%). The panel was identified, in order of predictive ability, as the secreted protein acidic and rich in cysteine (SPARC)-like 1 protein, fibrinogen alpha chain precursor, amyloid-β, apolipoprotein E precursor, serum albumin precursor, keratin type I cytoskeletal 9, and tetranectin.

When the model was applied to an independent blind dataset from MCI patients, the intensity of signals was intermediate between the control and AD patients implying that these markers could potentially predict patients with early neurodegenerative disease. The seven ion diagnostic paradigm was further validated using an independent cohort of samples, where the model was able to classify AD cases from controls with median accuracy of 84.5% (sensitivity 93.3%, specificity 75.7%). Validation by immunoassay was performed on the top three identified markers using the discovery samples and an independent sample cohort, which was from 17 postmortem confirmed AD patients.

Professor Kevin Morgan, from the Human Genomics and Molecular Genetics Institute at Nottingham and the principal author of the study said, "The findings are a new lead for improving early diagnosis of Alzheimer's disease. It will also be important to investigate what causes these specific proteins to change as Alzheimer's develops." The study was published in the February 2012 edition of the Journal of Alzheimer's Disease.

Related Links:

Nottingham Trent University



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.